Clinical trial
Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting…
NCT00162812 · Jules Bordet Institute, Other · Terminated
Key facts
| NCT number | NCT00162812 |
|---|---|
| Title | Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin |
| Official title | Prospective Evaluation of Topoisomerase II Alpha Gene Amplification and Protein Overexpression as Markers Predicting the Efficacy of Epirubicin in the Primary Treatment of Breast Cancer Patients |
| Acronym | TOP |
| Lead sponsor | Jules Bordet Institute, Other |
| Collaborators | Gustave Roussy, Cancer Campus, Grand Paris Centre Paul Strauss Centre Hospitalier du Luxembourg Clinique Louis Cathy - Baudour - Belgium HIS - Site Etterbeek - Ixelles - Belgium Clinique Saint Pierre… |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Epirubicin |
| Enrollment | 338 |
| Start date | Jan 1, 2003 |
| Primary completion | Dec 1, 2008 |
| Completion | Apr 1, 2009 |
| First posted | Sep 13, 2005 |
| Last update posted | Jul 18, 2008 |
| Countries | Belgium |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: